Dogma held that inhibition of the pleiotropic protein kinase glycogen synthase kinase-3 (GSK-3) was procarcinogenic due to its natural repression of β-catenin. Now, Wang et al. have found the reverse in certain leukemias, possibly paving the way for small-molecule GSK-3 inhibitors as selective anticancer agents.
